The CALGB is comprised of 26 academic medical centers and over 170 affiliated community hospitals joined in the pursuit of improved cancer treatment and an improved knowledge of tumor biology via controlled clinical trials. Over 2000 members of the group including physicians, statisticians, data managers, nurses, pharmacists, epidemiologists, and basic scientist; participate in these trials. From 25-35 phase III protocols are active at any one time, along with Phase II, Phase I and pilot studies required for the appropriate design of major randomized trials. In 1991 the CALGB accrued over 5,300 entries to its protocols. Multidisciplinary disease committees of the group design and implement protocols for the treatment of patients with leukemia, lymphoma, breast, respiratory and GI cancer. A GU Working Committee is responsible for a limited investigation of GU cancers using support from the pharmaceutical industry. The membership of these committees includes medical, radiation, and surgical oncologists, statisticians, data managers, psycho-oncologists, nurses and others. Modality Committees, including Pharmacology and Experimental Therapeutics, Psycho-Oncology, Surgery, Pathology, Radiation Oncology, Transplantation, Oncology Nursing, and Data Management serve as the sites for planning and implementing new approaches for these disciplines and most committees feed these concepts to the Disease Committees to be incorporated in the final design of protocols. In addition, the Group supports active investigation of tumor biology, epidemiology, pharmacology, and cancer control science through protocols developed and implemented via the Correlative Science Committee, the Epidemiology Working Committee, the Pharmacology and Experimental Therapeutics Committee and the Cancer Control Science Committee. The Group has developed specific protocols that address the common cancers of minorities and women and has promoted activities that encourage the participation of women and minorities in its clinical trials. Through appointments to key positions in the Group and with the support of the Minority Initiative Program funding, the CALGB has made significant progress in its minority and women program during the last funding period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA031946-13
Application #
2088267
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1982-04-01
Project End
1995-03-31
Budget Start
1994-04-26
Budget End
1995-03-31
Support Year
13
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Dartmouth College
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Morrison, Vicki A; McCall, Linda; Muss, Hyman B et al. (2018) The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). J Geriatr Oncol 9:228-234
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
Innocenti, Federico; Jiang, Chen; Sibley, Alexander B et al. (2018) Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep 8:16332
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Le-Petross, Huong T; McCall, Linda M; Hunt, Kelly K et al. (2018) Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). AJR Am J Roentgenol 210:669-676
McWilliams, Robert R; Foster, Nathan R; Mahoney, Michelle R et al. (2017) North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer 123:3494-3501
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Sinicrope, Frank A; Shi, Qian; Allegra, Carmen J et al. (2017) Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol 3:472-480

Showing the most recent 10 out of 627 publications